New drug targets mystery itch that Won't go away
NCT ID NCT07700056
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether remibrutinib, an oral drug, can reduce severe itching in adults who have had chronic itch for at least 4 months with no known cause. Participants receive either remibrutinib or a placebo for 52 weeks. The main goal is to see if more people on the drug achieve a meaningful reduction in itch intensity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- remibrutinib
- What this could lead to
- If effective, remibrutinib could offer a new treatment option for people suffering from severe chronic itch with no identifiable cause.
- What could go wrong
- This is a phase 3 trial, but the drug may not work better than placebo. Side effects are possible, and the cause of the itch is unknown, so results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PRURITUS OF UNKNOWN ORIGIN are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.